Table of Contents

1 Study Coverage

• 1.1 Bipolar Disorder Therapeutic Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Bipolar Disorder Therapeutic Market Size Growth Rate by Product
  • 1.4.2 Antipsychotics
  • 1.4.3 Anticonvulsants
  • 1.4.4 Mood Stabilizers
• 1.5 Market by End User
  • 1.5.1 Global Bipolar Disorder Therapeutic Market Size Growth Rate by End User
  • 1.5.2 Hospital Pharmacies
  • 1.5.3 Retail Pharmacies
  • 1.5.4 Online Pharmacies
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Bipolar Disorder Therapeutic Market Size
  • 2.1.1 Global Bipolar Disorder Therapeutic Revenue 2014-2025
  • 2.1.2 Global Bipolar Disorder Therapeutic Sales 2014-2025
• 2.2 Bipolar Disorder Therapeutic Growth Rate by Regions
  • 2.2.1 Global Bipolar Disorder Therapeutic Sales by Regions
  • 2.2.2 Global Bipolar Disorder Therapeutic Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Bipolar Disorder Therapeutic Sales by Manufacturers
  • 3.1.1 Bipolar Disorder Therapeutic Sales by Manufacturers
  • 3.1.2 Bipolar Disorder Therapeutic Sales Market Share by Manufacturers
  • 3.1.3 Global Bipolar Disorder Therapeutic Market Concentration Ratio (CR5 and HHI)
• 3.2 Bipolar Disorder Therapeutic Revenue by Manufacturers
  • 3.2.1 Bipolar Disorder Therapeutic Revenue by Manufacturers (2014-2019)
  • 3.2.2 Bipolar Disorder Therapeutic Revenue Share by Manufacturers (2014-2019)
• 3.3 Bipolar Disorder Therapeutic Price by Manufacturers
• 3.4 Bipolar Disorder Therapeutic Manufacturing Base Distribution, Product Types
  • 3.4.1 Bipolar Disorder Therapeutic Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Bipolar Disorder Therapeutic Product Type
  • 3.4.3 Date of International Manufacturers Enter into Bipolar Disorder Therapeutic Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Bipolar Disorder Therapeutic Sales by Product
• 4.2 Global Bipolar Disorder Therapeutic Revenue by Product
• 4.3 Bipolar Disorder Therapeutic Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Bipolar Disorder Therapeutic Breakdown Data by End User

6 North America

• 6.1 North America Bipolar Disorder Therapeutic by Countries
  • 6.1.1 North America Bipolar Disorder Therapeutic Sales by Countries
  • 6.1.2 North America Bipolar Disorder Therapeutic Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Bipolar Disorder Therapeutic by Product
• 6.3 North America Bipolar Disorder Therapeutic by End User

7 Europe

• 7.1 Europe Bipolar Disorder Therapeutic by Countries
  • 7.1.1 Europe Bipolar Disorder Therapeutic Sales by Countries
  • 7.1.2 Europe Bipolar Disorder Therapeutic Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Bipolar Disorder Therapeutic by Product
• 7.3 Europe Bipolar Disorder Therapeutic by End User

8 Asia Pacific

• 8.1 Asia Pacific Bipolar Disorder Therapeutic by Countries
  • 8.1.1 Asia Pacific Bipolar Disorder Therapeutic Sales by Countries
  • 8.1.2 Asia Pacific Bipolar Disorder Therapeutic Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Bipolar Disorder Therapeutic by Product
• 8.3 Asia Pacific Bipolar Disorder Therapeutic by End User

9 Central & South America

• 9.1 Central & South America Bipolar Disorder Therapeutic by Countries
  • 9.1.1 Central & South America Bipolar Disorder Therapeutic Sales by Countries
  • 9.1.2 Central & South America Bipolar Disorder Therapeutic Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Bipolar Disorder Therapeutic by Product
• 9.3 Central & South America Bipolar Disorder Therapeutic by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Bipolar Disorder Therapeutic by Countries
  • 10.1.1 Middle East and Africa Bipolar Disorder Therapeutic Sales by Countries
  • 10.1.2 Middle East and Africa Bipolar Disorder Therapeutic Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Bipolar Disorder Therapeutic by Product
• 10.3 Middle East and Africa Bipolar Disorder Therapeutic by End User

11 Company Profiles

• 11.1 Eli Lilly
  • 11.1.1 Eli Lilly Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Eli Lilly Bipolar Disorder Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Eli Lilly Bipolar Disorder Therapeutic Products Offered
  • 11.1.5 Eli Lilly Recent Development
• 11.2 Bristol-Myers Squibb
  • 11.2.1 Bristol-Myers Squibb Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Bristol-Myers Squibb Bipolar Disorder Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Bristol-Myers Squibb Bipolar Disorder Therapeutic Products Offered
  • 11.2.5 Bristol-Myers Squibb Recent Development
• 11.3 AstraZeneca
  • 11.3.1 AstraZeneca Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 AstraZeneca Bipolar Disorder Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 AstraZeneca Bipolar Disorder Therapeutic Products Offered
  • 11.3.5 AstraZeneca Recent Development
• 11.4 Allergan
  • 11.4.1 Allergan Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Allergan Bipolar Disorder Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Allergan Bipolar Disorder Therapeutic Products Offered
  • 11.4.5 Allergan Recent Development
• 11.5 Astellas Pharma
  • 11.5.1 Astellas Pharma Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Astellas Pharma Bipolar Disorder Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Astellas Pharma Bipolar Disorder Therapeutic Products Offered
  • 11.5.5 Astellas Pharma Recent Development
• 11.6 GlaxoSmithKline
  • 11.6.1 GlaxoSmithKline Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 GlaxoSmithKline Bipolar Disorder Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 GlaxoSmithKline Bipolar Disorder Therapeutic Products Offered
  • 11.6.5 GlaxoSmithKline Recent Development
• 11.7 Janssen Pharmaceuticals
  • 11.7.1 Janssen Pharmaceuticals Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Janssen Pharmaceuticals Bipolar Disorder Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Janssen Pharmaceuticals Bipolar Disorder Therapeutic Products Offered
  • 11.7.5 Janssen Pharmaceuticals Recent Development

12 Future Forecast

• 12.1 Bipolar Disorder Therapeutic Market Forecast by Regions
  • 12.1.1 Global Bipolar Disorder Therapeutic Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Bipolar Disorder Therapeutic Revenue Forecast by Regions 2019-2025
• 12.2 Bipolar Disorder Therapeutic Market Forecast by Product
  • 12.2.1 Global Bipolar Disorder Therapeutic Sales Forecast by Product 2019-2025
  • 12.2.2 Global Bipolar Disorder Therapeutic Revenue Forecast by Product 2019-2025
• 12.3 Bipolar Disorder Therapeutic Market Forecast by End User
• 12.4 North America Bipolar Disorder Therapeutic Forecast
• 12.5 Europe Bipolar Disorder Therapeutic Forecast
• 12.6 Asia Pacific Bipolar Disorder Therapeutic Forecast
• 12.7 Central & South America Bipolar Disorder Therapeutic Forecast
• 12.8 Middle East and Africa Bipolar Disorder Therapeutic Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Bipolar Disorder Therapeutic Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Bipolar disorder, also known as manic-depressive disorder, is a mental illness. It is a mental health problem that primarily affects mood. Symptoms of bipolar disorder are extreme irritability or agitation, a period of feeling empty, loss of interest in normal activities, sleep problems, etc. According to Pfizer, Inc., bipolar disorder affects over 5 million people in the U.S. Bipolar episodes are characterized by a drastic change in behavior and mood, and range from joyful and overexcited (manic episodes) to extremely sad and hopeless (depressive state). These disorders have different types of episodes such as manic episodes, hypomanic episodes, depressive episodes, and mixed episodes. Causes of bipolar disorders include childhood trauma, stressful life events, self-esteem problems, and genetic inheritance. People across the world marked “March 30” as a World Bipolar Day to spread awareness about the disorder and erase the stigma of mental illness. Large number of people suffering from this mental condition resort to drinking to lift their mood. According to the National Institute on Alcohol Abuse and Alcoholism, 27.6% of the people with bipolar disorder become addicted to alcohol, while over 16% engaged in alcohol abuse.
The growing need to reduce the financial burden of bipolar disorder will drive the growth prospects for the global bipolar disorder therapeutic market until the end of 2021. It has been observed that governments and companies across the globe are increasingly organizing awareness camps to raise disease awareness among the public, reduce the burden of mental disorders in vulnerable groups, ensure the rights of people with mental disorders, and make treatment facilities accessible to them. Consequently, such awareness initiatives help to curb the overall monetary loss, reduce their effect on the global economy, and improve the quality of life for patients. Such factors will raise public awareness about mental disorders and treatments and in turn, propel the rate of revenue generation in the market.
The Americas accounted for the majority market share during 2016 and will continue to dominate the market during the forecasted period. Some of the major factors responsible for the market's growth in the region are the high incidence of bipolar disorder symptoms in the US, the growing number of pipeline products, the rising awareness about these disorders in the region, and the growing prevalence of pediatric bipolar disorders.
The global Bipolar Disorder Therapeutic market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Bipolar Disorder Therapeutic market based on company, product type, end user and key regions.

This report studies the global market size of Bipolar Disorder Therapeutic in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Bipolar Disorder Therapeutic in these regions.
This research report categorizes the global Bipolar Disorder Therapeutic market by top players/brands, region, type and end user. This report also studies the global Bipolar Disorder Therapeutic market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Eli Lilly
Bristol-Myers Squibb
AstraZeneca
Allergan
Astellas Pharma
GlaxoSmithKline
Janssen Pharmaceuticals

Market size by Product
Antipsychotics
Anticonvulsants
Mood Stabilizers
Market size by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Bipolar Disorder Therapeutic market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Bipolar Disorder Therapeutic market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Bipolar Disorder Therapeutic companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Bipolar Disorder Therapeutic submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Bipolar Disorder Therapeutic are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Bipolar Disorder Therapeutic market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.